Judge any IPO valuation: post-issue P/E vs listed peers, EPS dilution, NAV, debt, and the red flags that matter before applying.
The only P/E that matters is on the fully-diluted, post-issue share count — pre-issue EPS flatters every IPO. Take the upper band price ÷ post-issue EPS. Then compare against the median P/E of listed peers named in the RHP's own peer table (not random companies): cheaper than median is interesting, 25%+ premium needs an earnings-growth story to justify it.
The Fundamental X-Ray scores exactly these pillars — growth, valuation-vs-peers, promoter structure, risk — with every point traceable to its inputs on the IPO page, and the full rulebook on the methodology page. Use it as a checklist, not a verdict: scores organise evidence, they don't replace judgment.
There is no universal good number — only good relative to listed peers and growth. Post-issue P/E near or below peer median with growing PAT is reasonable; 2x peer median needs exceptional, verifiable growth.
New shares dilute earnings across more shares. Always divide by the post-issue share count — pre-issue EPS overstates cheapness.
No. Subscription measures demand, not value — grey-market heat and herd bidding routinely overpay. Valuation is checked against earnings and peers, never against subscription.
Last updated: 13 Oct 2026, 23:04 IST